Equities

Novartis AG

0QLR:LSE

Novartis AG

  • Price (CHF)120.36
  • Today's Change0.82 / 0.69%
  • Shares traded1.67m
  • 1 Year change21.63%
  • Beta0.7783
Data delayed at least 20 minutes, as of Feb 06 2026 18:28 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Novartis AG grew revenues 8.91% from 51.72bn to 56.33bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 17.11% net income growth from 11.94bn to 13.98bn.
Gross margin75.82%
Net profit margin24.79%
Operating margin31.00%
Return on assets13.10%
Return on equity31.01%
Return on investment17.82%
More ▼

Cash flow in USDView more

In 2025, Novartis AG did not generate a significant amount of cash. However, the company earned 19.14bn from its operations for a Cash Flow Margin of 33.99%. In addition the company used 4.88bn on investing activities and also paid 14.87bn in financing cash flows.
Cash flow per share7.44
Price/Cash flow per share17.41
Book value per share18.65
Tangible book value per share-3.58
More ▼

Balance sheet in USDView more

Novartis AG has a Debt to Total Capital ratio of 43.18%, a lower figure than the previous year's 52.07%.
Current ratio1.12
Quick ratio0.8868
Total debt/total equity0.7669
Total debt/total capital0.4318
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)3.82%
Div growth rate (5 year)6.62%
Payout ratio (TTM)64.08%
EPS growth(5 years)15.26
EPS (TTM) vs
TTM 1 year ago		21.92
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.